CRDF Q4 2022 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$128,000-3.8% YoY

Gross Profit

$128,000100.0% margin

Operating Income

-$9M-7337.5% margin

Net Income

-$9M-6794.5% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+37.6%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$116M

Total Liabilities

$10M

Stockholders' Equity

$106M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$128,000	$133,000	-3.8%
Gross Profit	$128,000	$133,000	-3.8%
Operating Income	-$9M	-$10M	+1.4%
Net Income	-$9M	-$9M	+7.9%